title: [Hodgkin's disease during pregnancy. Study of late effects in the newborn infants].
abstract: An analysis of the possible late effects in 15 children of mothers with Hodgkin Disease, who were given combined chemotherapy during pregnancy, including five who were in the first trimester of development, was conducted. None of the newborns were found to have congenital abnormalities during birth. The 15 children, ranging in ages between 4 to 17, are alive, showing both normal physical and psychomotor development, as well as normal laboratory and cytogenetic results. The thirteen mothers who were in complete remission as a result of the chemotherapy used at recommended dosages and at accepted intervals, are alive and without any evidence of the illness, considering them as cured. Based on these results, pregnancy should not be considered as a contraindication for the adequate treatment of Hodgkin's disease, since those fetuses who received cytotoxic agents in utero, did not show a greater incidence of congenital malformations and have not shown any evidence of side-effects due to the chemotherapy.
authors.affiliation: Departamento de Hematologia y Oncologia Médica, Hospital de Oncología, Instituto Mexicano del Seguro Social, D.F.
authors.forename: A
authors.initials: A
authors.lastname: Avilés
authors.forename: G
authors.initials: G
authors.lastname: Zepeda
authors.forename: J
authors.initials: J
authors.lastname: Cruz
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000453:epidemiology / Q000209:etiology; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D002871:Chromosome Banding; D000075202:Contraindications; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005333:Fetus / Q000187:drug effects*; D006130:Growth Disorders / Q000139:chemically induced / Q000453:epidemiology; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage / Q000009:adverse effects; D001523:Mental Disorders / Q000139:chemically induced / Q000453:epidemiology; D008800:Mexico / Q000453:epidemiology; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D011297:Prenatal Exposure Delayed Effects; D011344:Procarbazine / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D012189:Retrospective Studies; D014747:Vinblastine; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D001761:Bleomycin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D011241:Prednisone
vernacular_title: Enfermedad de Hodgkin durante el embarazo. Estudio de efectos tardíos en los recién nacidos.